Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Rubius Therapeutics (Nasdaq:RUBY) announced that its CEO, Pablo J. Cagnoni, M.D., will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rubius Therapeutics (Nasdaq:RUBY) announced that its CEO, Pablo J. Cagnoni, M.D., will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020. The presentation is scheduled for 3:15 p.m. GMT/10:15 a.m. EST. A live audio webcast will be accessible on the company's website, with an archived replay available for 90 days post-event. Rubius specializes in genetically engineering red blood cells to create Red Cell Therapeutics™, aiming to treat cancer and autoimmune diseases through innovative cellular therapies.
Details
News Market Reaction – RUBY
The recorded move for RUBY in the trading session of this news was +0.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 3:15 p.m. GMT/10:15 a.m. EST.
A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics, Inc. (Nasdaq:RUBY) is a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® genetically engineers and cultures Red Cell Therapeutics to create selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of cancer and autoimmune diseases. Rubius’ initial product candidates are designed to activate and expand immune system function to fight cancer and modulate the immune system to induce tolerance for the treatment of autoimmune diseases. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Investors
Lori Melançon, Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com
Media
Marissa Hanify, Director, Corporate Communications
Marissa.hanify@rubiustx.com
Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.